2° Convegno Nazionale

IL TEAM INTERDISCIPLINARE NEL CARCINOMA DELLA PROSTATA

NEGRAR DI VALPOLICELLA 6-7 DICEMBRE 2019

Sala Perez - IRCCS Ospedale Sacro Cuore Don Calabria



La malattia organo confinata: carcinoma prostatico ad alto rischio.

CASO CLINICO


Carlo Messina, MD


U.O.C. Oncologia Medica Ospedale S. Chiara, Trento

carlo.messina@apss.tn.it

Clinical presentation

- \checkmark 56 year old patient
- ✓ No remarkable past medical history
- ✓ PSA baseline 20 ng/ml
- Rectal exploration revealed a suspicious prostatic nodule
- ✓ US-trans rectal prostate biopsy: 12/16 + specimens for adenocarcinoma
 Gleason score 8= 4+4
- ✓ Pelvic MRI: likely cT3
- Bone scan and CT scan were negative for local and distant mets





Clinical presentation

Overall Clinical stage:

- PSA= 20 ng/ml
- cT3 N0 M0
- Gleason score: 8=4+4

Radical prostatectomy or radiotherapy \mp ADT for high risk localized prostate cancer.... This is the dilemma....

Risk groups for localized prostate cancer¹:

Low riskT1-T2a and GS ≤ 6 and PSA ≤ 10 Intermediate riskT2b and/or GS7 and/or PSA10-20High risk \geq T2c or GS8-10 or PSA >20

GS, Gleason score; PSA, prostate-specific antigen.



Case presentation

Pathological Clinical stage:

- pT3b N+ 2/16 M0 R0
- Gleason score: 8=4+4
- Post-op PSA= 1 ng/ml
- Post-op PET choline: negative
- Locally advanced disease

Tumour board opinion: RT + ADT


Radiotherapy \mp ADT or upfront ADT.... This is the dilemma....




Case presentation

- PSA= 0.04 ng/ml at 3 and 6 months after salvage RT + ADT
- PSA = 1,5 ng/ml after 18 months of ADT confirmed in two consecutive PSA measurement.
- Bicalutamide 50 mg was added to ADT
- PSA= 2 ng/ ml and 3 ng/ml at 3 and 6 months of CAD
- CT scan, bone scan and PET choline: negative for local and distant metastasis






Who are nmCRPC patients?




1. Paller CJ et al. *Clin Adv Hematol Oncol.* 2013;11(1):14-23; 2. Arlen PM, et al. J Urol. 2008 Jun;179(6):2181-5; 3. Smith MR, et al. J Clin Oncol. 2013 Oct 20;31(30):3800-6; 4. Freedland SJ, et al. J Clin Oncol. 2007 May 1;25(13):1765-71; 5. Howard LE et al. BJU Int. 2017 Nov;120(5B):E80-E86.

Phase III randomized trials in High-Risk nmCRPC




Similar trials with Enzalutamide (PROSPER)¹, Apalutamide (SPARTAN)², Darolutamide (ARAMIS)³

1.Hussain, NEJM 2018; 2.Matthew, NJM 2018; 3.Fizazi, NEJM 2019



Months

The patient received apalutamide 240 mg daily as compassionate use program....



...CT scan and bone scan were performed every 16 weeks...



...No evidence of disease recurrence with conventional imaging at 12 months...

...The treatment has been well tolerated and he is keeping on treatment with apalutamide 240 mg ...